An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT00696995

BIASP-1917

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions

Enrollment: 509 patients

Sex: All

Ages: Under 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Type 2 diabetes
• Insulin-naive or previously treated by basal only insulin therapy

Exclusion criteria

• Patients who are unlikely to comply with the protocol
• Pregnancy or breastfeeding or intention of becoming pregnant

Trial design

509 participants in 1 patient group

A

Treatment:

Drug: biphasic insulin aspart 30